УКР  |  ENG

Клинические исследования в Украине

Форум Пациентам

Исследования / № 00338247

Описание
Краткое названиеEAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer
Полное названиеAn Open-Label Expanded Access Study of Lapatinib and Capecitabine Therapy in Subjects With ErbB2 Overexpressing Locally Advanced or Metastatic Breast Cancer
СпонсорGlaxoSmithKline
Industry
ИсточникGlaxoSmithKline
Под контролемUnited States: Food and Drug Administration
Australia: Department of Health and Ageing Therapeutic Goods Administration
Краткое описаниеThis study will provide pre-approval drug access to lapatinib, in combination with
capecitabine, to patients whose breast cancer had progressed on other therapies
СостояниеИдет набор
Дата началаJuly 2006
ФазаPhase 4
Вид исследованияAllocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Набор0
КритерииInclusion criteria:

- May have received prior lapatinib in another trial. Previous capecitabine (as
previous agent or non-lapatinib containing regimen) is also permitted.

- Prior treatment with hormonal therapy is allowed.

- Must have advanced or metastatic breast cancer with progression (as assessed by
modified RECIST) after prior therapy, which must include all of the following: prior
treatment with an anthracycline, a taxane, and trastuzumab alone or in combination
with other therapy. Trastuzumab must have been administered in the adjuvant, or
locally advanced or metastatic setting.

- Must have tumors that overexpress ErbB2 defined as +3 by IHC or FISH positive for
ErbB2 gene amplification. The status of ErbB2 expression must be documented prior to
study entry.

- Must be >/= 18 years of age

- Life expectancy of > 8 weeks

- Must have recovered from side effects of previous treatment

- Patients with CNS mets are eligible provided treatment with prohibited medications as
listed in the protocol are not required

- Cardiac ejection fraction must be within the institutional range of normal as
measured by ECHO. MUGA scans are allowed if ECHOs cannot be performed

- Able to swallow and retain oral medications

- Must have adequate hematologic, hepatic and renal function

Exclusion criteria:

- Pregnant or lactating females

- Malabsorption syndrome, disease significantly affecting GI function, or resection of
the stomach or bowel, or ulcerative colitis

- Concurrent disease or condition that would make the patient inappropriate for study
participation

- Unresolved or unstable toxicity from prior administration of another investigational
drug and/or prior cancer treatment

- Uncontrolled infection

- Active cardiac disease defined as history of uncontrolled or symptomatic angina;
history of arrhythmias requiring medication, or clinically significant, with the
exception of asymptomatic atrial fibrillation requiring anticoagulation; MI < 6
months from study entry; uncontrolled or symptomatic CHF; ejection fraction below the
institutional normal limit; any other cardiac condition that would make this protocol
unreasonably hazardous for the patient

- Receiving concurrent chemotherapy (other than capecitabine), radiation therapy,
immunotherapy, biologic therapy or hormonal therapy for cancer. Concurrent therapy
with bisphosphonates is allowed

- History of allergic reaction attributed to compounds of similar composition to
lapatinib or any excipients

- History of allergic reactions attributed to compounds of similar chemical composition
to capecitabine, fluorouracil or excipients

- Known DPD deficiency
ПолBoth
Минимальный возраст18 Years
Максимальный возрастN/A
УсловиеBreast Cancer
Применяемое лечение
Druglapatinib + capecitabine
Контакты и расположение
Chernivtsi , 58013GSK Investigational Site
Kiev , 03115GSK Investigational Site
Odessa , 65055GSK Investigational Site
Rovno , 33010GSK Investigational Site
2011 © Клинические испытания в Украине